Search results
Results from the WOW.Com Content Network
Hodgkin lymphoma (HL) is a type of lymphoma in which cancer originates from a specific type of white blood cell called lymphocytes, where multinucleated Reed–Sternberg cells (RS cells) are present in the patient's lymph nodes. [2][8] The condition was named after the English physician Thomas Hodgkin, who first described it in 1832. [9][10 ...
ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs: Adriamycin (also known as doxorubicin / hydroxydaunorubicin, designated as H in CHOP) Bleomycin. Vinblastine. Dacarbazine (similar to procarbazine, designated as ...
October 16, 2024 at 5:00 PM. A new study suggests that the immunotherapy nivolumab can improve the survival rate for advanced Hodgkin lymphoma patients. (George Frey/Reuters) An immunotherapy ...
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
122–184. Lymphoma is the most common form of hematological malignancy, or "blood cancer", in the developed world. Taken together, lymphomas represent 5.3% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States and 55.6% of all blood cancers.
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20 -positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.
MOPP (chemotherapy) MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: (M) ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) (O) ncovin (also known as Vincristine or VCR) (P) rocarbazine (also known as Matulane or Natulan)
BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. [3] There also exists a more intensive regimen ...